HC Wainwright Has Positive View of Vor Biopharma Q4 Earnings

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for Vor Biopharma to a loss of $0.83 per share from a projected loss of $0.94; it also forecast a $3.26-per-share loss for FY2027.
• Vor reported a quarterly loss of $1.45 per share, missing analysts’ $0.81 loss estimate by $0.64 per share.
• Analyst opinion is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus and a $38.29 average price target, while one firm rates the stock Sell and others range from Hold to Strong Buy.

Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - Investment analysts at HC Wainwright lifted their Q4 2026 EPS estimates for shares of Vor Biopharma in a report issued on Monday, November 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.83) per share for the quarter, up from their previous estimate of ($0.94). The consensus estimate for Vor Biopharma's current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vor Biopharma's Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.79) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($2.10) EPS, FY2029 earnings at $1.50 EPS and FY2030 earnings at $3.90 EPS.

A number of other brokerages also recently commented on VOR. Stifel Nicolaus set a $40.00 price objective on shares of Vor Biopharma in a research report on Monday. Citigroup raised shares of Vor Biopharma to a "strong-buy" rating in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Vor Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday. William Blair assumed coverage on Vor Biopharma in a report on Wednesday, October 21st. They set an "outperform" rating for the company. Finally, Wedbush boosted their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $38.29.

Vor Biopharma Stock Up 3.2%

NASDAQ VOR opened at $19.86 on Wednesday. The firm's fifty day moving average price is $20.61 and its two-hundred day moving average price is $17.39. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $26.00.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.64).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Braidwell LP boosted its position in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after acquiring an additional 106,330 shares during the period. Renaissance Technologies LLC bought a new position in Vor Biopharma during the first quarter worth about $2,298,000. Bank of America Corp DE increased its position in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock worth $2,014,000 after acquiring an additional 112,496 shares during the period. Bank of New York Mellon Corp acquired a new stake in Vor Biopharma in the 2nd quarter worth about $1,799,000. Finally, Alps Advisors Inc. raised its stake in Vor Biopharma by 42.5% in the 3rd quarter. Alps Advisors Inc. now owns 78,371 shares of the company's stock worth $1,495,000 after purchasing an additional 23,373 shares in the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor's platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.